Back to Search Start Over

Case series of BRAF‐mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy.

Authors :
Fujimura, Taku
Yoshino, Koji
Kato, Hiroshi
Fujisawa, Yasuhiro
Nakamura, Yoshiyuki
Yamamoto, Yuki
Kunimoto, Kayo
Ito, Takamichi
Matsushita, Shigeto
Maekawa, Takeo
Ohuchi, Kentaro
Amagai, Ryo
Muto, Yusuke
Furudate, Sadanori
Kambayashi, Yumi
Hashimoto, Akira
Aiba, Setsuya
Source :
Journal of Dermatology; Mar2021, Vol. 48 Issue 3, p397-400, 4p
Publication Year :
2021

Abstract

The efficacy of encorafenib plus binimetinib (E + B) combination therapy for BRAF‐mutated advanced melanoma as second‐line therapy and beyond is still unknown. In this report, we investigated 22 cases of BRAF‐mutated advanced melanoma treated with E + B combination therapy. The objective response rate (ORR) for the total cohort was 68.4%. Notably, the ORR for the second‐line and beyond cohort was 73.3%, suggesting that the therapeutic effect of E + B combination therapy is comparable with that of first‐line targeted therapy. In contrast, overall survival and progress‐free survival in our present cohort was worse than that in a previous clinical trial. Notably, although the incidence rate of severe adverse events was higher than that in a previous report, our present study suggested that E + B combination therapy is a well‐tolerated antimelanoma regimen. Our present study suggested that the efficacy and safety profile of E + B combination therapy as a second‐line therapy and beyond is comparable with that of first‐line targeted therapy. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
03852407
Volume :
48
Issue :
3
Database :
Complementary Index
Journal :
Journal of Dermatology
Publication Type :
Academic Journal
Accession number :
148996040
Full Text :
https://doi.org/10.1111/1346-8138.15688